Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
- Previous Close
41.81 - Open
41.58 - Bid 41.71 x --
- Ask 41.72 x --
- Day's Range
41.50 - 42.88 - 52 Week Range
25.48 - 47.50 - Volume
3,862,400 - Avg. Volume
5,128,946 - Market Cap (intraday)
46.723B - Beta (5Y Monthly) -0.02
- PE Ratio (TTM)
134.58 - EPS (TTM)
0.31 - Earnings Date --
- Forward Dividend & Yield 0.62 (1.47%)
- Ex-Dividend Date May 15, 2025
- 1y Target Est
59.54
Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
www.haisco.comRecent News: 002653.SZ
View MorePerformance Overview: 002653.SZ
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002653.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002653.SZ
View MoreValuation Measures
Market Cap
46.82B
Enterprise Value
47.73B
Trailing P/E
134.87
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.28
Price/Book (mrq)
11.38
Enterprise Value/Revenue
12.36
Enterprise Value/EBITDA
103.26
Financial Highlights
Profitability and Income Statement
Profit Margin
9.07%
Return on Assets (ttm)
1.78%
Return on Equity (ttm)
10.05%
Revenue (ttm)
3.86B
Net Income Avi to Common (ttm)
350.11M
Diluted EPS (ttm)
0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
1.3B
Total Debt/Equity (mrq)
53.70%
Levered Free Cash Flow (ttm)
-210.54M